Venture Market July 23, 2026: CuspAI's $450 Million Round at $2.6 Billion Valuation, Neo's Stealth Exit with $100 Million, Deals by Natural, Empirical Security, Infinity, Brenus Pharma, and Plazza, Analysis of Capital Shifts in AI's Control Layer for Venture Investors and Funds
Today's Prime Topic: The venture market has shifted from paying for access to models to paying for control over choke points surrounding them. CuspAI’s $450 million round at a $2.6 billion valuation, Neo's stealth exit at $100 million, and a wave of strategic investments from corporations and private equity are reshaping the logic of capital distribution. We explore what this means for venture funds and LPs.
Venture investments in mid-July 2026 are not widely distributed across the startup market. Capital is clearly skewing towards infrastructure, security, and software that sits within the control layer of artificial intelligence rather than the presentation layer. The largest check of the cycle has gone to AI materials development, while other notable rounds have clustered around cybersecurity, inference software, payment rails for AI agents, and automation of regulated workflows.
This combination is significant for investment committees. It shows that funds still want exposure to AI but are increasingly preferring businesses that shape the computation economy, control data, or manage critical enterprise processes, rather than simply piling on yet another thin layer over a frontier model.
Deal of the Day: CuspAI Raises $450 Million at $2.6 Billion Valuation
The Series B round for UK-based CuspAI has become the defining transaction of the week as it indicates where deep-pocketed investors see the next defensive moat in AI—not just in models but in the physical systems that these models help design.
- Round Size: $450 million, Series B, valuation of $2.6 billion.
- Consortium: Led by Kleiner Perkins and NEA, with participation from Bezos Expeditions, the UK government, AMD Ventures, Lux Capital, Glade Brook Capital Partners, and Invest-NL.
- Total Funding: Over $650 million within just two years of launch.
- Headquarters: Cambridge, UK.
The company utilizes AI to discover new materials, focusing on semiconductors, batteries, clean energy, and advanced manufacturing. Investors are intrigued by the fact that these materials lie upstream of several constrained markets. If AI can reduce the semiconductor industry's reliance on rare metals, shorten R&D cycles, or enhance energy materials, the returns will not be limited to software multiples—they will cascade into manufacturing economics, supply chain resilience, and geopolitical competitiveness.
A hard lesson for founders here is that such a level of capital intensity in deep tech is only funded when the project is tied to strategic industrial demand rather than an abstract scientific promise.
Cybersecurity as a Magnet for Venture Capital
The second large cluster of deals is cybersecurity, and it's not coincidental. AI is not just creating new categories of software; it is rewriting the risk model for existing ones.
Neo: $100 Million Exit from Stealth
Boston-based Neo has raised $100 million in a combined seed and Series A round led by Andreessen Horowitz, Bessemer Venture Partners, Craft Ventures, and Merlin Ventures. The company was founded by former SentinelOne executives Nick Warner and Shlomi Salem alongside technologist Eran Shirazi. The thesis is straightforward: traditional corporate security tools are not well-suited to the world of AI applications and agent systems. The platform allows security teams to see, validate, and control AI software before data access or automated actions create new operational risks. The technology is already undergoing pilots in finance, energy, and transportation.
Empirical Security: $25 Million for Exploit Prediction
The Chicago firm raised a Series A led by Brightmind Partners, with participation from HPA and Costanoa Ventures, bringing total funding to $37 million. The positioning deserves attention: instead of broad rhetoric about "AI security," the company focuses on predicting threats through monitoring exploited vulnerabilities. Budgets are opening faster for software that helps prioritize specific weaknesses than for platforms promising merely "more intelligence."
Second Order AI Stack: Software That Makes Hardware Usable
A seed round for Infinity at $15 million with a post-money valuation of $100 million deserves separate attention. The company is building a software layer that makes any AI chip ready for inference.
The investment thesis here is simple: new chips don’t matter if developers can’t quickly deploy on them. Nvidia's dominance in AI is largely due to software and ecosystem maturity, not just hardware performance. Infinity is effectively selling time to usefulness: if new silicon manufacturers can become inference-ready in days instead of months or years, they have a chance to compete for manufacturing demand.
A deeper signal is that venture capital is taking the "second order AI stack" seriously. The market has already spent huge sums on model developers and chip companies. The next dollars are flowing to translators, adapters, and orchestration layers that make this infrastructure usable.
Agent Commerce: Payment Rails for AI
The startup Natural has closed a $30 million Series A led by Kirsten Green from Forerunner, bringing its total funding to $40 million. The company addresses a challenge that will grow with every viable agent scenario: how software executes financial actions on behalf of a user or company without chaos in access rights, payment friction, and compliance issues.
The logic of investors is clear:
- Agent commerce is easy to demonstrate but hard to bring to industrial scale.
- Once software starts buying software, paying vendors, and handling transactional processes, the product becomes the rails themselves.
- The owner of this layer captures volume, compliance, and embedded distribution far beyond the capabilities of a thin app.
This gives the company a more sustainable position than many applied AI startups, whose differentiation erodes as foundational models improve. For founders, the distinction is crucial: AI that saves a click will struggle to attract funding; AI that safely moves a dollar attracts strategic capital.
The Return of Strategic Capital: PE, Corporations, and Distribution Channels
One of the most telling features of the current market is the noticeable share of strategically important financings that have come not from classic venture funds but from private equity, corporate, and ecosystem partners.
- Quorum (Washington) received an undisclosed strategic investment from Enlightenment Capital. The AI-based government affairs platform serves more than 2,000 organizations, including over half of the Fortune 100 companies. Capital is earmarked for executing the product roadmap and expanding agent AI capabilities.
- Wagmo (New York) secured strategic investment from Curql to bring modern veterinary health insurance into the credit union channel—an example of distribution-oriented capital.
- HALO X-ray Technologies (Nottingham, UK) closed a multi-million round led by Agilent with participation from the UK Innovation Science Seed Fund and Midland Engine Investment Fund to complete regulatory approval for an X-ray diffraction technology in screening systems.
When buyers, channels, or industry experts can fund part of the next chapter of growth, founders become less reliant on purely financial sponsors. In a tighter capital market, this is an advantage.
Biotech and Healthcare: Funding Linked to Milestones, Not Narratives
Lyon-based Brenus Pharma added €11 million to its Series A round, bringing total funding since inception to €38 million. The extension is tied to achieving clinical, regulatory, and business development milestones around STC-1010—the leading clinical immunotherapeutic program for stomach and colorectal cancer. The company noted the arrival of new investors from Europe and the Asia-Pacific region.
Such extensions are important as an indicator of underwriting risk. Instead of forcing every company to undergo a new narrative reboot, investors are willing to add capital when the team has sufficiently de-risked the science. This often proves healthier than a completely new round at an inflated valuation, as it directly ties capital to progress.
In India, Plazza (Bangalore) secured $15 million in Series A led by Accel, Elevation Capital, and Nexus Venture Partners to expand its pharmacy network and offer instant medicine delivery. This is a bet on logistics and trust in a category where reliability matters more than brand storytelling: accessibility, order fulfillment rates, inventory routing, and area coverage density form a genuine defensive moat.
Geography of Capital: A Market Without a Single Template
The current venture pipeline is geographically mixed but uneven:
- The US dominates early-stage software and cybersecurity—Neo, Empirical Security, Infinity.
- The UK secured the largest check of the cycle with CuspAI and demonstrated strength in deep tech with government capital involvement.
- France emerged through biotech and clinically validated assets.
- India entered the conversation via operationally dense healthcare commerce, not through frontier AI.
Global venture is not converging into a single template. Different regions attract capital where they already possess a density of talent, regulatory competence, or operational advantage.
Cycle Risks: Where Venture Funds May Overpay
The discipline of the current market does not negate structural threats to portfolios:
- Commodity Risk. AI applications built on widely available models may grow, but sustainable capital is gravitating beneath or around the model layer.
- Uneven Disclosure. A significant portion of strategically interesting transactions takes place without disclosure of amounts, complicating the benchmarking of valuations.
- Capital Intensity in Deep Tech. Computation, lab processes, and industrial partnerships are expensive, leading to continuous dilution of early investors’ stakes.
- Concentration in Narrow Categories. When the market primarily pays for infrastructure, security, and science, the correlation of risks within portfolios increases.
- Dependence on Regulatory Milestones. In biotech and physical security, approval timelines remain a primary source of uncertainty.
Conclusions for Venture Investors and Funds
The current deal flow reflects a market that seeks to evaluate not novelty but where AI creates sustainable scarcity. In some cases, it is scarce scientific expertise, as with CuspAI. In others, it is scarce trust, as seen in cybersecurity and public policy software. In still others, it is scarce operational reliability, as in drug delivery.
Practical takeaways for investment committees:
- Finance choke points, not slogans. If a startup addresses infrastructure costs, security posture, compliance processes, or long-term order fulfillment, large rounds can still be underwritten.
- Seek accumulated defensibility. Scientific intellectual property and industrial partnerships, founder reputation, ecosystem leverage, progress on scientific milestones—the common denominator is not technology but the ability to make a replacement painful.
- Consider the type of investor as a value factor. Sometimes the most valuable investor is not the one paying the highest price but the one providing the cheapest and surest route to customers.
- Ask what the next dollar changes. Extensions, strategic investments, and concentrated early rounds are pushing out broad syndication on hype—both sides of the market are becoming more disciplined.
- Bet on layers around autonomy. Payments, security, chips, science, and workflow infrastructure benefit from AI while remaining difficult to commoditize. This is likely where premium multiples will concentrate.
The next phase of startup financing looks less like a race to bolt AI onto everything and more like a competition to control systems that make AI safe, deployable, and economically viable. Companies securing capital now are not just promising automation— they are defining who controls the choke points around it.
